Yanni Souroutzidis
Stock Analyst at Cantor Fitzgerald
(0.30)
# 4,485
Out of 4,703 analysts
6
Total ratings
16.7%
Success rate
-32.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanni Souroutzidis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Maintained: Buy | $3.68 | $1.79 | +105.59% | 3 | Sep 1, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiated Coverage: Buy | $17 | $15.78 | +7.73% | 1 | Aug 19, 2026 | |
| TRDA Entrada Therapeutics | Initiated Coverage: Buy | n/a | $7.13 | - | 1 | Apr 1, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Initiated Coverage: Buy | n/a | $12.45 | - | 1 | Mar 11, 2026 |
Karyopharm Therapeutics
Sep 1, 2026
Maintained: Buy
Price Target: $3.68
Current: $1.79
Upside: +105.59%
AgomAb Therapeutics NV
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $15.78
Upside: +7.73%
Entrada Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $7.13
Upside: -
Satellos Bioscience Inc.
Mar 11, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $12.45
Upside: -